UJ9 Stock Overview
Develops, manufactures, and commercializes biologics in Mainland China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Shandong Boan Biotechnology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.89 |
| 52 Week High | HK$2.06 |
| 52 Week Low | HK$0.89 |
| Beta | 0 |
| 11 Month Change | -15.24% |
| 3 Month Change | -8.72% |
| 1 Year Change | -49.43% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -53.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| UJ9 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -11.9% | -0.2% | 0.8% |
| 1Y | -49.4% | -16.9% | 9.1% |
Return vs Industry: UJ9 underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: UJ9 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| UJ9 volatility | |
|---|---|
| UJ9 Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: UJ9 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: UJ9's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 777 | Hua Jiang | www.boan-bio.com |
Shandong Boan Biotechnology Co., Ltd. develops, manufactures, and commercializes biologics in Mainland China and internationally. Its commercialized products include Boyounuo (BA1101) bevacizumab injection for the treatment of metastatic or recurrent non-small cell lung cancer (NSCLC), recurrent glioblastoma, epithelial ovarian, fallopian tube or primary peritoneal cancer, and cervical cancer; and Boyoubei BA6101, a human immunoglobulin G2 monoclonal antibody for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The company develops BA1102 denosumab injection to treat patients with skeletal-related events caused by multiple myeloma and bone metastases from solid tumors, as well as giant cell tumour of bone; BA5101 dulaglutide injection indicated for glycemic control in adults with type-2 diabetes; and BA9101 aflibercept intravitreous injection to treat neovascular wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinopathy of prematurity.
Shandong Boan Biotechnology Co., Ltd. Fundamentals Summary
| UJ9 fundamental statistics | |
|---|---|
| Market cap | €500.00m |
| Earnings (TTM) | €8.13m |
| Revenue (TTM) | €94.74m |
61.5x
P/E Ratio5.3x
P/S RatioIs UJ9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UJ9 income statement (TTM) | |
|---|---|
| Revenue | CN¥719.84m |
| Cost of Revenue | CN¥186.46m |
| Gross Profit | CN¥533.38m |
| Other Expenses | CN¥471.57m |
| Earnings | CN¥61.81m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 74.10% |
| Net Profit Margin | 8.59% |
| Debt/Equity Ratio | 47.0% |
How did UJ9 perform over the long term?
See historical performance and comparison